IHInge R. Holtman

Inge R. Holtman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Inge R. Holtman has a total of 290 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Parkinson’s disease genetic risk converges on Lewy body pathology-associated microglial states

    by Raphael Kübler, Daniele Mattei, J. Oriol Narcis, Claudia De Sanctis, Kosei Hirata, Alice Buonfiglioli, Ariana Chriss, Mikaela Rosen Perez, Felix A. Crary, Emma L. Thorn, et al.

    Parkinson’s disease (PD) and related α-synucleinopathies are defined by the spread of Lewy body (LB) pathology across vulnerable brain regions, yet how substantia nigra (SN) myeloid cells respond remains unresolved. Using SOX10-based oligodendrocyte depletion and CD11b-based myeloid enrichment, we profiled 169,799 brain myeloid cells and nuclei from 96 donors spanning the LB continuum, including 86,427 from the SN, and integrated them with AMP PD for a total of 298,592 profiles. Across eight conserved states, α-synucleinopathy is associated with a bidirectional signature: upregulated glycolytic and proteostatic-stress programs alongside downregulated lysosomal and mitochondrial pathways. Microglia shift from P2RY12-high sensome cells toward an HSP90AA1-high proteostatic stress state, a transition that intensifies at late Braak LB stages. Immunohistochemistry confirmed that HSP60 + proteostatic microglia state proportions increase with SN neuron loss. A rare NUCKS1-high state (∼1% of myeloid cells), more abundant in late-stage disease, carried the strongest PD polygenic-risk loading. The PD-protective rs3732765-A allele, a microglial cis-eQTL that lowers P2RY12 expression, was nominally associated with a higher proportion of P2RY12-high microglia and higher lysosomal program activity. These findings frame microglial involvement as structured and genetically tractable, nominating the P2RY12 genetic axis and NUCKS1-high microglia for mechanistic studies.

  • Open Access

    Predicting Relevant Microglia‐Associated Cell–Cell Communication Pathways in Alzheimer's Disease: A Role for SPP1

    by Janssen M. Kotah, Marina Trombetta Lima, Esmée C. Dragt, Asimenia Voulgaroglou, Nieske Brouwer, Inge R. Holtman, Susanne M. Kooistra, Bart J. L. Eggen

    Microglia play a key role in the pathophysiology of Alzheimer's Disease (AD) and their increased heterogeneity likely affects disease progression. We previously identified distinct microglial signatures that were enriched in AD donors and associated with amyloid and tau, respectively. Here we generated a snRNAseq dataset from postmortem control and AD cases and analyzed alterations in cell–cell communication pathways that might be relevant to AD pathophysiology. One signaling pathway perturbed in AD cases involved SPP1 , and while this pathway was also present in control samples, microglia–microglia SPP1 signaling was restricted to AD donors. Further analyses within microglia–microglia signaling predict AD‐specific induction of GAS6‐AXL signaling (from inflammatory and ribosomal microglia), and SPP1‐ITGAV/ITGB5 signaling (from disease‐associated and inflammatory microglia, among others). Together, these findings might in part explain the increased microglia phagocytic profile described in AD. RNAscope confirmed enrichment of SPP1 expressing microglia near amyloid plaques in AD brain tissue samples. These data indicate altered cellular communications between microglia in the AD brain.


  • Open Access

    Dynamic interplay of polygenic risk across brain disorders, neuropathological endophenotypes, and neuropsychiatric symptoms

    by Nienke Jacobine Mekkes, Shivam Kumar, Eric Hoekstra, Alejandro Marmolejo Garza, Ekaterina Dagkesamanskaia, Dennis Wever, Minke Groot, Karim L. Kreft, Ana Rajicic, Harro Seelaar, et al.

    Neurodegenerative and psychiatric brain disorders show substantial heterogeneity in clinical and neuropathological manifestations, possibly reflecting both distinct and shared pathogenic mechanisms. Our understanding of brain disorder heterogeneity is limited by the scarcity of deeply phenotyped, multi-modal post-mortem brain bank cohorts. Here, we integrated genotype, clinical and neuropathological data from 2,553 Netherlands Brain Bank donors to investigate how genetic risk contributes to disease manifestations. Disease-specific polygenic risk scores revealed extensive cross-disorder enrichment of genetic risk, suggesting shared pathogenic mechanisms beyond diagnostic boundaries. Donors with frontotemporal lobar degeneration carrying C9orf72 repeat expansions showed elevated polygenic risk for multiple disorders, indicating that genetic variation may modify monogenic disease expression. Neuropsychiatric symptoms were associated with distinct personality-trait polygenic risk profiles across disorders, highlighting diagnosis-dependent genetic contributions to clinical heterogeneity. Together, our findings demonstrate the value of this unique resource and reveal a dynamic interplay of genetic risk across brain disorders.


  • Interpretation of Neurodegenerative GWAS Risk Alleles in Microglia and their Interplay with Other Cell Types

    by Inge R. Holtman, Christopher K. Glass, Alexi Nott

    Microglia have been implicated in numerous neurodegenerative and neuroinflammatory disorders; however, the causal contribution of this immune cell type is frequently debated. Genetic studies offer a unique vantage point in that they infer causality over a secondary consequence. Genome-wide association studies (GWASs) have identified hundreds of loci in the genome that are associated with susceptibility to neurodegenerative disorders. GWAS studies implicate microglia in the pathogenesis of Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and to a lesser degree suggest a role for microglia in vascular dementia (VaD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), and other neurodegenerative and neuropsychiatric disorders. The contribution and function of GWAS risk loci on disease progression is an ongoing field of study, in which large genomic datasets, and an extensive framework of computational tools, have proven to be crucial. Several GWAS risk loci are shared between disorders, pointing towards common pleiotropic mechanisms. In this chapter, we introduce key concepts in GWAS and post-GWAS interpretation of neurodegenerative disorders, with a focus on GWAS risk genes implicated in microglia, their interplay with other cell types and shared convergence of GWAS risk loci on microglia.


  • Open Access

    Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions

    by Alyse de Boer, Aletta M R van Den Bosch, Nienke J Mekkes, Nina L Fransen, Ekaterina Dagkesamanskaia, Eric Hoekstra, Jörg Hamann, Joost Smolders, Inge Huitinga, Inge R Holtman

    Multiple sclerosis (MS) is a heterogeneous neurological disorder with regards to clinical presentation and pathophysiology. Here, we investigated the heterogeneity of MS by performing an exploratory factor analysis on quantitative and qualitative neuropathology data collected for 226 MS donors in the Netherlands Brain Bank autopsy cohort. Three promising dimensions were identified and subsequently validated with clinical, neuropathological, and genetic data. Dimension 1 ranged from a predominance of remyelinated and inactive lesions to extensive pathological changes, higher proportions of active and mixed lesions, and foamy microglia morphology. This pattern was positively correlated with more severe disease, the presence of B and T cells, and neuroaxonal damage. Scoring high on dimension 2 was associated with active lesions, reactive sites, and the presence of nodules. These donors had less severe disease, a specific pattern of cortical lesions, and MS risk variants in the human leukocyte antigen region, the latter indicating a connection between disease onset and this neuropathological dimension. Donors scoring high on dimension 3 showed increased lesional pathology with relatively more mixed and inactive lesions and ramified microglia morphology. This pattern was associated with longer disease duration, subpial cortical lesions, less involvement of the adaptive immune system, and less axonal damage. Taken together, the three dimensions may represent (1) demyelination and immune cell activity associated with pathological and clinical progression, (2) microglia (re)activity and possibly lesion initiation, and (3) loss of lesion activity and scar formation. Our findings highlight that a thorough understanding of the interplay between multiple pathological characteristics is crucial to understand the heterogeneity of MS pathology, as well as its association with genetic predictors and disease outcomes. The scores of donors on the dimensions can serve as an important starting point for further disentanglement of MS heterogeneity and translation into observations and interventions in living cohorts with MS.


  • Open Access

    Identification of clinical disease trajectories in neurodegenerative disorders with natural language processing

    by Nienke J. Mekkes, Minke Groot, Eric Hoekstra, Alyse de Boer, Ekaterina Dagkesamanskaia, Sander Bouwman, Sophie M. T. Wehrens, Megan K. Herbert, Dennis D. Wever, Annemieke Rozemuller, et al.

    Neurodegenerative disorders exhibit considerable clinical heterogeneity and are frequently misdiagnosed. This heterogeneity is often neglected and difficult to study. Therefore, innovative data-driven approaches utilizing substantial autopsy cohorts are needed to address this complexity and improve diagnosis, prognosis and fundamental research. We present clinical disease trajectories from 3,042 Netherlands Brain Bank donors, encompassing 84 neuropsychiatric signs and symptoms identified through natural language processing. This unique resource provides valuable new insights into neurodegenerative disorder symptomatology. To illustrate, we identified signs and symptoms that differed between frequently misdiagnosed disorders. In addition, we performed predictive modeling and identified clinical subtypes of various brain disorders, indicative of neural substructures being differently affected. Finally, integrating clinical diagnosis information revealed a substantial proportion of inaccurately diagnosed donors that masquerade as another disorder. The unique datasets allow researchers to study the clinical manifestation of signs and symptoms across neurodegenerative disorders, and identify associated molecular and cellular features.


  • Open Access

    Genetic insights into immune mechanisms of Alzheimer’s and Parkinson’s disease

    by Alexi Nott, Inge R. Holtman

    Microglia, the macrophages of the brain, are vital for brain homeostasis and have been implicated in a broad range of brain disorders. Neuroinflammation has gained traction as a possible therapeutic target for neurodegeneration, however, the precise function of microglia in specific neurodegenerative disorders is an ongoing area of research. Genetic studies offer valuable insights into understanding causality, rather than merely observing a correlation. Genome-wide association studies (GWAS) have identified many genetic loci that are linked to susceptibility to neurodegenerative disorders. (Post)-GWAS studies have determined that microglia likely play an important role in the development of Alzheimer’s disease (AD) and Parkinson’s disease (PD). The process of understanding how individual GWAS risk loci affect microglia function and mediate susceptibility is complex. A rapidly growing number of publications with genomic datasets and computational tools have formulated new hypotheses that guide the biological interpretation of AD and PD genetic risk. In this review, we discuss the key concepts and challenges in the post-GWAS interpretation of AD and PD GWAS risk alleles. Post-GWAS challenges include the identification of target cell (sub)type(s), causal variants, and target genes. Crucially, the prediction of GWAS-identified disease-risk cell types, variants and genes require validation and functional testing to understand the biological consequences within the pathology of the disorders. Many AD and PD risk genes are highly pleiotropic and perform multiple important functions that might not be equally relevant for the mechanisms by which GWAS risk alleles exert their effect(s). Ultimately, many GWAS risk alleles exert their effect by changing microglia function, thereby altering the pathophysiology of these disorders, and hence, we believe that modelling this context is crucial for a deepened understanding of these disorders.


  • Open Access

    Identification of neuropathology-based subgroups in multiple sclerosis using a data-driven approach

    by Alyse de Boer, Aletta M.R. van Den Bosch, Nienke J. Mekkes, Nina Fransen, Eric Hoekstra, Joost Smolders, Jörg Hamann, Inge Huitinga, Inge R. Holtman

    Multiple sclerosis (MS) is a heterogeneous disorder with regards to clinical presentation and pathophysiology. Stratification into biologically distinct subgroups could enhance prognostication and efficacious allocation to disease-modifying therapies. In this study, we identified MS subgroups by performing a clustering analysis on neuropathology data collected for MS donors in the Netherlands Brain Bank (NBB) autopsy cohort. The input dataset contained detailed information on white matter lesion load, the proportion of active, mixed active/inactive, inactive and remyelinating lesions, microglia morphology in these lesions, and the presence of microglial nodules, perivascular cuffs and cortical lesions for 228 donors. A factor analysis was performed to reduce noise and redundancy prior to hierarchical clustering with K-means consolidation. Four subgroups with distinct patterns of white matter lesions were identified. These were subsequently validated with additional clinical, neuropathological and genetic data. The subgroups differed with regards to disease progression and duration, the timing of motor, sensory and other relevant signs and symptoms, patterns of cortical lesions and the presence of B cells. Age at MS onset and sex, previously associated with milder forms of MS, did not differ between the subgroups; the subgroups could also not be distinguished based on the manifestation of clinical signs and symptoms. The available genetic data was used to calculate MS polygenic risk scores (PRSs) for donors included in the NBB cohort. The MS PRS did not differ between the subgroups, but was significantly correlated with the first and second dimension of the factor analysis, the latter lending genetic support to our subdivision. Taken together, these findings suggest a complex relationship between neuropathological subgroups and clinical characteristics, indicating that post-mortem cohort studies are critical to better stratify patients and understand underlying neuropathophysiological mechanisms, in order to ultimately achieve personalised medicine in MS.

  • Open Access

    Natural language processing and modeling of clinical disease trajectories across brain disorders

    by Nienke Mekkes, Minke Groot, Sophie Wehrens, Eric Hoekstra, Megan K Herbert, Maaike Brummer, Dennis Wever, Bart J.L. Eggen, Annemieke Rozenmuller, Inge Huitinga, et al.

    Brain disorders, including neurodegenerative diseases and mental illnesses, are often difficult to diagnose and study due to clinical and pathological heterogeneity, overlap in clinical manifestations between disorders, and frequent comorbidities, hampering drug development and fundamental research. Hence, there is a clear need for data-driven approaches to disentangle these complex disorders. Here, we established a computational pipeline to process clinical summaries from donors with a wide range of brain disorders that were neuropathologically diagnosed by the Netherlands Brain Bank. First, we identified and defined 90 cross-disorder signs and symptoms within cognitive, motor, sensory, psychiatric, and general domains. Second, we trained and optimized natural language processing (NLP) models to identify these signs and symptoms in individual sentences of the extensive clinical summaries from donors of the NBB, resulting in temporal disease trajectories. Third, we studied the temporal manifestation and survival profiles across rare and complex dementias, alpha-synucleinopathies, frontotemporal dementia subtypes, and mental illnesses, giving new insight into how symptomatology differs in manifestation and temporal profiles across brain disorders. Lastly, we trained a recurrent neural network to predict the Neuropathological Diagnosis. Taken together, this integrated approach resulted in a highly unique resource that can facilitate research into cross-disorder symptomatology.